UY39006A - Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting - Google Patents

Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting

Info

Publication number
UY39006A
UY39006A UY0001039006A UY39006A UY39006A UY 39006 A UY39006 A UY 39006A UY 0001039006 A UY0001039006 A UY 0001039006A UY 39006 A UY39006 A UY 39006A UY 39006 A UY39006 A UY 39006A
Authority
UY
Uruguay
Prior art keywords
sting
compositions
compounds
conditions associated
treat conditions
Prior art date
Application number
UY0001039006A
Other languages
English (en)
Inventor
Jason Katz
Hans Martin Seidel
Shankar Venkatraman
William R Roush
Original Assignee
Ifm Due Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifm Due Inc filed Critical Ifm Due Inc
Publication of UY39006A publication Critical patent/UY39006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta divulgación caracteriza entidades químicas (por ejemplo, un compuesto o una sal aceptable desde el punto de vista farmacéutico, y/o un hidrato, y/o un cocristal, y/o una combinación de fármaco del compuesto) que inhiben (por ejemplo, antagoniza) el estimulador de genes de interferón (STING). Dichas entidades químicas son útiles, por ejemplo, para tratar una afección, una enfermedad o un trastorno en el que una activación de STING (por ejemplo, señalización de STING) aumentada (por ejemplo, excesiva) contribuye a la patología y/o síntomas y/o progresión de la afección, la enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano.
UY0001039006A 2019-12-31 2020-12-30 Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting UY39006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962955839P 2019-12-31 2019-12-31
US202063090538P 2020-10-12 2020-10-12

Publications (1)

Publication Number Publication Date
UY39006A true UY39006A (es) 2021-07-30

Family

ID=74206237

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039006A UY39006A (es) 2019-12-31 2020-12-30 Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting

Country Status (7)

Country Link
US (1) US20230127839A1 (es)
EP (1) EP4085051A1 (es)
JP (1) JP2023509422A (es)
CN (1) CN115348957A (es)
TW (1) TW202136239A (es)
UY (1) UY39006A (es)
WO (1) WO2021138434A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020010092A1 (en) 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20240100017A1 (en) 2020-12-22 2024-03-28 Ifm Due, Inc. Methods of treating cancer
US20240122903A1 (en) 2020-12-22 2024-04-18 Ifm Due Inc. Methods of treating cancer
EP4267127A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
WO2022140397A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN116023321A (zh) * 2022-12-30 2023-04-28 中国药科大学 Sting抑制剂前药及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) * 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
AU2014340269B2 (en) 2013-10-21 2018-06-21 Drexel University Use of STING agonists to treat chronic hepatitis B virus infection
WO2020191227A1 (en) * 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes

Also Published As

Publication number Publication date
CN115348957A (zh) 2022-11-15
TW202136239A (zh) 2021-10-01
US20230127839A1 (en) 2023-04-27
WO2021138434A1 (en) 2021-07-08
JP2023509422A (ja) 2023-03-08
EP4085051A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
UY38751A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
UY39006A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
UY38905A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
UY39005A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
CO2019008932A2 (es) Imidazo-quinolinas sustituidas como moduladores de nlrp3
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
BR112018071347A2 (pt) moduladores de nlrp3
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
UY39328A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
UY39608A (es) Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting
CL2019001552A1 (es) Agonistas duales acilados de glp-1/glp-2.
CU20180143A7 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
PE20221259A1 (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras
ECSP21018584A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
WO2016141296A8 (en) Tricyclic kinase inhibitors of melk and methods of use
AR122086A1 (es) Derivados de purina como inhibidores del sik-3
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
ZA202208085B (en) Therapeutic use of long-acting conjugate of triple agonist having activity with respect to all of glucagon and glp-1 and gip receptors against lung disease
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.